I'm sure your doctor can tell you everything you need to know about liver X. It may be for TBI but it does say recovery.
Abstract
Traumatic
brain injury (TBI) increases Alzheimer’s disease (AD) risk and leads to
the deposition of neurofibrillary tangles and amyloid deposits similar
to those found in AD. Agonists of Liver X receptors (LXRs), which
regulate the expression of many genes involved in lipid homeostasis and
inflammation, improve cognition and reduce neuropathology in AD mice.
One pathway by which LXR agonists exert their beneficial effects is
through ATP-binding cassette transporter A1 (ABCA1)-mediated lipid
transport onto apolipoprotein E (apoE). To test the therapeutic utility
of this pathway for TBI, we subjected male wild-type (WT) and apoE−/−
mice to mild repetitive traumatic brain injury (mrTBI) followed by
treatment with vehicle or the LXR agonist GW3965 at 15 mg/kg/day. GW3965
treatment restored impaired novel object recognition memory in WT but
not apoE−/− mice. GW3965 did not significantly enhance the spontaneous
recovery of motor deficits observed in all groups. Total soluble Aβ
40 and Aβ
42
levels were significantly elevated in WT and apoE−/− mice after injury,
a response that was suppressed by GW3965 in both genotypes. WT mice
showed mild but significant axonal damage at 2 d post-mrTBI, which was
suppressed by GW3965. In contrast, apoE−/− mice showed severe axonal
damage from 2 to 14 d after mrTBI that was unresponsive to GW3965.
Because our mrTBI model does not produce significant inflammation, the
beneficial effects of GW3965 we observed are unlikely to be related to
reduced inflammation. Rather, our results suggest that both
apoE-dependent and apoE-independent pathways contribute to the ability
of GW3965 to promote recovery from mrTBI.
No comments:
Post a Comment